BACKGROUND: Genetic association studies using case-control designs are susceptible to false-positive and false-negative results if there are differences in genetic ancestry between cases and controls. We measured genetic ancestry among Latinas in a population-based case-control study of breast cancer and tested the association between ancestry and known breast cancer risk factors. We reasoned that if genetic ancestry is associated with known breast cancer risk factors, then the results of genetic association studies would be confounded. METHODS: We used 44 ancestry informative markers to estimate individuals' genetic ancestry in 563 Latina participants. To test whether ancestry is a predictor of hormone therapy use, parity, and body mass index (BMI), we used multivariate logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (95% CI) associated with a 25% increase in Indigenous American ancestry, adjusting for age, education, and the participant's and grandparents' place of birth. RESULTS: Hormone therapy use was significantly less common among women with higher Indigenous American ancestry (OR, 0.78; 95% CI, 0.63-0.96). Higher Indigenous American ancestry was also significantly associated with overweight (BMI, 25-29.9 versus <25) and obesity (BMI, > or =30 versus <25), but only among foreign-born Latina women (OR, 3.44; 95% CI, 1.97-5.99 and OR, 1.95; 95% CI, 1.24-3.06, respectively). CONCLUSION: Some breast cancer risk factors are associated with genetic ancestry among Latinas in the San Francisco Bay Area. Therefore, case-control genetic association studies for breast cancer should directly measure genetic ancestry to avoid potential confounding.
BACKGROUND: Genetic association studies using case-control designs are susceptible to false-positive and false-negative results if there are differences in genetic ancestry between cases and controls. We measured genetic ancestry among Latinas in a population-based case-control study of breast cancer and tested the association between ancestry and known breast cancer risk factors. We reasoned that if genetic ancestry is associated with known breast cancer risk factors, then the results of genetic association studies would be confounded. METHODS: We used 44 ancestry informative markers to estimate individuals' genetic ancestry in 563 Latina participants. To test whether ancestry is a predictor of hormone therapy use, parity, and body mass index (BMI), we used multivariate logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (95% CI) associated with a 25% increase in Indigenous American ancestry, adjusting for age, education, and the participant's and grandparents' place of birth. RESULTS: Hormone therapy use was significantly less common among women with higher Indigenous American ancestry (OR, 0.78; 95% CI, 0.63-0.96). Higher Indigenous American ancestry was also significantly associated with overweight (BMI, 25-29.9 versus <25) and obesity (BMI, > or =30 versus <25), but only among foreign-born Latina women (OR, 3.44; 95% CI, 1.97-5.99 and OR, 1.95; 95% CI, 1.24-3.06, respectively). CONCLUSION: Some breast cancer risk factors are associated with genetic ancestry among Latinas in the San Francisco Bay Area. Therefore, case-control genetic association studies for breast cancer should directly measure genetic ancestry to avoid potential confounding.
Authors: Esteban González Burchard; Luisa N Borrell; Shweta Choudhry; Mariam Naqvi; Hui-Ju Tsai; Jose R Rodriguez-Santana; Rocio Chapela; Scott D Rogers; Rui Mei; William Rodriguez-Cintron; Jose F Arena; Rick Kittles; Eliseo J Perez-Stable; Elad Ziv; Neil Risch Journal: Am J Public Health Date: 2005-10-27 Impact factor: 9.308
Authors: R M Cerda-Flores; G K Kshatriya; T K Bertin; D Hewett-Emmett; C L Hanis; R Chakraborty Journal: Ann Hum Biol Date: 1992 Jul-Aug Impact factor: 1.533
Authors: Robert W Haile; Esther M John; A Joan Levine; Victoria K Cortessis; Jennifer B Unger; Melissa Gonzales; Elad Ziv; Patricia Thompson; Donna Spruijt-Metz; Katherine L Tucker; Jonine L Bernstein; Thomas E Rohan; Gloria Y F Ho; Melissa L Bondy; Maria Elena Martinez; Linda Cook; Mariana C Stern; Marcia Cruz Correa; Jonelle Wright; Seth J Schwartz; Lourdes Baezconde-Garbanati; Victoria Blinder; Patricia Miranda; Richard Hayes; George Friedman-Jiménez; Kristine R Monroe; Christopher A Haiman; Brian E Henderson; Duncan C Thomas; Paolo Boffetta Journal: Cancer Prev Res (Phila) Date: 2012-02
Authors: Melinda C Aldrich; Steve Selvin; Helen M Hansen; Lisa F Barcellos; Margaret R Wrensch; Jennette D Sison; Charles P Quesenberry; Rick A Kittles; Gabriel Silva; Patricia A Buffler; Michael F Seldin; John K Wiencke Journal: Am J Epidemiol Date: 2008-09-12 Impact factor: 4.897
Authors: L Fejerman; S S Sanchez; R Thomas; P Tachachartvanich; J Riby; S L Gomez; E M John; M T Smith Journal: Carcinogenesis Date: 2016-07-13 Impact factor: 4.944
Authors: Ju Yeon Jung; Pil-Won Kang; Eungsoo Kim; Diego Chacon; Dominik Beck; Dennis McNevin Journal: Int J Legal Med Date: 2019-08-07 Impact factor: 2.686
Authors: Kami K White; Song-Yi Park; Laurence N Kolonel; Brian E Henderson; Lynne R Wilkens Journal: Int J Cancer Date: 2012-01-27 Impact factor: 7.396
Authors: Danny S Park; Itamar Eskin; Eun Yong Kang; Eric R Gamazon; Celeste Eng; Christopher R Gignoux; Joshua M Galanter; Esteban Burchard; Chun J Ye; Hugues Aschard; Eleazar Eskin; Eran Halperin; Noah Zaitlen Journal: Genet Epidemiol Date: 2017-11-08 Impact factor: 2.135
Authors: Lisa M Hines; Rebecca L Sedjo; Tim Byers; Esther M John; Laura Fejerman; Mariana C Stern; Kathy B Baumgartner; Anna R Giuliano; Gabriela Torres-Mejia; Roger K Wolff; Kylie K Harrall; Martha L Slattery Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-08 Impact factor: 4.254